About Augmenix UK Ltd

Our Vision

The Augmenix vision is to improve the lives of cancer patients receiving radiation therapy. Augmenix UK Ltd. is a UK company based in Corby, Northamptonshire offering radiation oncology products using its proprietary hydrogel technology. Augmenix is using this technology to develop products that decrease unintended radiation damage to normal organs during radiation therapy and to mark soft tissue.

“It is my personal goal to be able to provide global access to SpaceOAR hydrogel, a minimally invasive intervention, that significantly benefits patients by reducing the side effects of radiation exposure. This is why I’m so excited about the benefits of creating space between the prostate and the rectum for men undergoing radiation treatment. Even in the modern era of more precise dose delivery through IMRT, optimised planning and a better understanding of patient stabilisation, a little bit of space has been shown to make a big difference” – Stephen McGill, Vice President & General Manager, International.

Developing Advanced Hydrogel Spacing for Radiotherapy

augmenix_logo_largeFounded in 2007, Augmenix is focused on improving the outcomes of radiotherapy through the use of absorbable hydrogels. The company is using this technology to develop products that decrease unintended radiation damage to normal organs during radiation therapy and to mark soft tissue. Augmenix UK Ltd was established in 2017 to provide warehousing, logistics and customer support across Europe.


SpaceOAR® Hydrogel to Minimise Radiation Exposure

SpaceOAR hydrogel may help prevent rectal bleeding and rectal injury for patients undergoing radiation therapy for prostate cancer

Whilst many patients with prostate cancer are successfully treated with radiotherapy, there are known risks and side effects that result from radiation damage to organs and tissues in close proximity to the prostate.

Tumour irradiation can sometimes result in the injury of nearby healthy tissues (OARs – Organs At Risk). The presence of nearby healthy tissues often force the clinician into a compromise – deliver enough radiation to maximize destruction of the cancerous tumours or reduce the radiation to minimize harm to surrounding tissue and potential side effects.

To answer this challenge in prostate cancer radiotherapy, Augmenix developed  SpaceOAR® Hydrogel, an absorbable hydrogel that temporarily moves the rectum away from the prostate and the high-intensity radiation zone. This extra space helps maximise the radiation dose to the prostate gland, avoid unnecessary irradiation of surrounding tissue and minimize harmful side-effects

SpaceOAR Hydrogel received positive NICE guidance in 2017 and CE mark approved in 2010.